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authorization for coverage of COX-2 inhibitors. Evi-
dence-based coverage criteria limit these drugs to mem-
bers who are at moderate to high-risk of NSAID-induced
GI events. Regence was interested in the economic impact
of the COX-2s. However, cost-effectiveness data were
not available from the manufacturers. OBJECTIVES: 1)
To evaluate the cost impact of COX-2 inhibitors on a
managed care population. 2) To determine the appropri-
ateness (in economic terms) of the prior authorization
criteria. METHODS: The VIGOR trial assessed the de-
velopment of clinically important ulcer events and com-
plicated upper GI events, including perforation, obstruc-
tion, and bleeding (POBs), in patients using either
rofecoxib or naproxen. Using the same DRGs and ICD9
codes in the VIGOR study, Regence obtained their own
patient data for these events in the year 2000. The num-
ber needed to treat (NNT), cost to prevent one clinically
significant upper GI event, and the cost to prevent one
complicated upper GI event (needing hospitalization)
were calculated from the data presented in the VIGOR
trial. RESULTS: The average COX-2 drug cost per pa-
tient per year is $1,100. The cost to prevent one clinically
significant NSAID-induced upper GI event is $46,000,
and the cost to prevent one NSAID-induced complicated
upper GI event requiring hospitalization, is $137,500. In
the year 2000, 443 Regence members were hospitalized
for an upper GI POB with a total cost of nearly $4 mil-
lion (average $9030 per hospitalization). CONCLU-
SIONS: In the absence of complete cost-effectiveness
data, a large health plan conducted a simple, yet very use-
ful cost impact analysis to support and inform drug pol-
icy for COX-2 inhibitors. The cost per hospitalization
avoided is much higher than the actual hospitalization
costs. This supported the Regence decision to limit cover-
age of COX-2 inhibitors to a moderate to high-risk popu-
lation.
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Number Needed to Treat (NNT) is calculated in clinical
trials by taking the inverse of the difference in absolute
risk in the placebo group from the treatment group. It
captures how many people would need to receive a treat-
ment to prevent a disease or event. OBJECTIVES: To de-
termine the roles of treatment efficacy and population
characteristics in Number Needed to Treat (NNT) calcu-
lations within randomized clinical trials of osteoporosis
pharmacological agents. METHODS: Data were col-
lected from publications of three major clinical trials of
pharmacological osteoporosis agents. Trials valuated
were the Multiple Outcomes of Raloxifene Evaluation
(MORE), Fracture Intervention Trial 1&2 (FIT) which
evaluated Alendronate, and Vertebral Efficacy with
Risedronate Therapy (VERT). NNT, mean age, baseline
Bone Mineral Density (BMD) at spine, baseline vertebral
fracture rate, vertebral fracture rates in the placebo and
treatment groups, and relative risk reductions were ab-
stracted. RESULTS: The Number Needed to Treat not
only varied among different agents but also in different
populations where the same treatment was used. The
MORE trial reported two NNTs. The “MORE 1” trial,
where few participants had a prevalent vertebral fracture
(11%), found an NNT of 46 while “MORE 2”, where
most participants had a prevalent vertebral fracture
(88%), found an NNT of 16. FIT1, where all participants
had prevalent vertebral fractures, reported an NNT of 15
while FIT2, no participants had a prevalent fracture, re-
ported an NNT of 60. The VERT trial’s NNT was calcu-
lated to be 20 using the above method. VERT had an
80% prevalent vertebral fracture rate. CONCLUSION:
Variation in NNT is due to the different characteristics
like placebo fracture rates as well as treatment efficacy. If
one compares the trials with the most similar placebo
group fracture rates, “MORE2”, FIT1, and VERT, the
Number Needed to Treat is quite similar. Dissimilar pop-
ulation characteristics as opposed to differences in treat-
ment efficacy can be responsible for differences in NNT.
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OBJECTIVE: The importance of assessing fatigue in
rheumatoid arthritis (RA) has been confirmed in numer-
ous studies. Several instruments are available to assess fa-
tigue, however, the psychometric properties of most have
been determined in various populations other than RA
and the instruments tend to measure different aspects of
fatigue. The objective of this study was to assess the per-
formance of two fatigue instruments, one was developed
in the RA population and the other in a nondisease-spe-
cific population. METHODS: This study is an ongoing
prospective, multi-center, observational study conducted
to document long-term functional, clinical, humanistic
and economic outcomes, and treatment patterns in pa-
tients with new onset rheumatoid arthritis. Two fatigue
instruments were used to assess RA patients: The Func-
tional Assessment of Chronic Illness Therapy-Fatigue
Subscale (FACIT-F), an instrument used primarily in on-
cology populations, and the Multidimensional Assess-
ment of Fatigue (MAF), developed in an RA population.
MAF measures four dimensions of fatigue (severity, dis-
tress, degree of interference in daily activities, and tim-
ing). At baseline, patients were requested to complete
both the 16-item, MAF and the 13-item, FACT-F via tele-
phone interview. Using baseline data only, the correlation
between the MAF and the FACIT-F was tested in 133 pa-
tients with early RA (signs and symptoms 3 months and
